MUPIROCIN (mupirocin calcium) by PharmaIN is 12. Approved for secondarily infected traumatic skin lesions (up to 10 cm in length, 100 cm in area) due to susceptible isolates of staphylococcus aureus (s, 100 cm in area) due to susceptible isolates of staphylococcus aureus and 1 more indications. First approved in 2020.
Drug data last refreshed 23h ago
12.1 Mechanism of Action Mupirocin is an RNA synthetase inhibitor antibacterial [see ] . 12.3 Pharmacokinetics Absorption Systemic absorption of mupirocin through intact human skin is minimal. The systemic absorption of mupirocin was studied following application of mupirocin cream 3 times daily…
Worked on MUPIROCIN at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
Impact of Mupirocin Decolonization on the Nasal Microbiome
Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin